Quarterly report · Q1
9273.TEDINET S100SAN2
Period2023-07-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.8bn | 2023-07-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.4bn | 2022-07-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥1.2bn | 2023-07-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥1.0bn | 2022-07-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2023-07-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥4.1bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥979m | 2022-07-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.2bn | 2023-07-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥979m | 2022-07-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥758m | 2023-07-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥606m | 2022-07-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥758m | 2023-07-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥606m | 2022-07-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥28.7bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥28.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥26.3bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.4bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥7.5bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥21.2bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥20.9bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥18.8bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.6bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥19.12 | 2023-07-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.83 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.29 | 2022-07-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 74.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-09-30 | −¥449m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-09-30 | −¥449m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | −¥15m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥4.0bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥3.6bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥449m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥686m |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥2.2bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥2.2bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥526m |
| —segment total | revenue | 2023-07-01 → 2023-09-30 | ¥6.3bn |
| —segment total | revenue external | 2023-07-01 → 2023-09-30 | ¥5.8bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥449m |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | ¥1.2bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥501m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥501m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | ¥6m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥3.5bn |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥501m |
| jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥672m |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥337m |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥5.9bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥5.4bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥501m |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 346
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)東 陽 監 査 法 人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)浅 山 英 夫 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)田 部 秀 穂 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 5358608000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 5823138000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 22052802000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 979315000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 1191036000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 4091865000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 605900000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 757585000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 2687220000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 604856000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 763788000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 2693461000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 18834883000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 21211853000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 20923488000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 26250193000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 28654702000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 28464493000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 15.29 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 19.12 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 67.83 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.7175 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.7403 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.7351 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 39619980 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 39619980 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 39619980 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 39619980 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1300 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 39599500 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 395995 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 19180 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 39619980 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 395995 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 1300 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 1300 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |